Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m. BST) on Tuesday, May 5, 2026 to discuss the company’s first quarter financial results.

CEO Richard Pops said the company is entering what he described as a “really exciting year” as the orexin agonist field moves ...

A Relative Strength Rating upgrade for Alkermes shows improving technical performance. Will it continue?

Investors in Alkermes plc ALKS need to pay close attention to the stock based on moves in the options market lately. That is because the May 15, 2026 $50.00 Call had some of the highest implied ...

View Alkermes Public Limited Company ALKS stock quote prices, financial information, real-time forecasts, and company news from CNN.

Alkermes (NASDAQ:ALKS) is gearing up to announce its quarterly earnings on Thursday, 2024-10-24. Here's a quick overview of what investors should know before the release. Analysts are estimating that ...

(Reuters) -Alkermes said on Wednesday it will acquire Avadel Pharmaceuticals in a deal valued at up to $2.1 billion, gaining an approved sleep-disorder treatment and expanding into the sleep medicine ...

As stripped down and divested Alkermes enters 2024 as a “pure-play neuroscience company”—as described by CEO Richard Pops on a conference call on Thursday—much will depend on the success of new ...

Alkermes plans to spin out its oncology research division into a standalone entity, creating a potential value-unlocking transaction. The spin-off will allow Alkermes to focus on its neuroscience ...

DUBLIN, Oct. 31, 2023 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced that the Registration Statement on Form 10, as amended (Form 10), filed by Mural Oncology plc (Mural Oncology) was ...

Alkermes plc (Nasdaq: ALKS) today announced that it will begin accepting applications for its inaugural Alkermes Pathways APN Research Awards™ program on Monday, March 16, 2026. This competitive grant ...